The Recurrence Score^® Result

The Recurrence Score result is based on the quantitative analysis of the expression of 21 genes within the patient’s tumour sample.

Prognosis

Your patient’s individualised 9-year distant recurrence risk (%) with endocrine therapy alone.*

*based on the TAILORx or NSABP B-14 trials^1,4

Prediction

The Group Average Absolute Chemotherapy Benefit is the potential reduction in distant recurrence risk across all ages within this range of Recurrence Score results when chemotherapy is added to endocrine treatment.*

Confidence Interval Range

The 95% confidence intervals provide the likely range of values for these measures.

Exploratory Subgroup Analysis

This table provides additional data about potential chemotherapy benefit based on age and Recurrence Score risk group.*

*based on the TAILORx or NSABP B-20 clinical trial populations.^2-4

Single-Gene Scores

Quantitative ER, PR, and HER2 scores by RT-PCR, specific to your patient. These are on the report for quality control purposes.

Estimated Chemotherapy Benefit

The NSABP B-20 study randomised patients to treatment with tamoxifen (TAM) alone or tamoxifen plus chemotherapy (TAM + CT) and validated that Recurrence Score results are predictive of chemotherapy benefit.

Learn more about NSABP B-20→

Estimated Chemotherapy Benefit

The TAILORx study is a prospective trial in which patients with Recurrence Score results between 11-25 were randomly assigned endocrine therapy (ET) or endocrine plus chemotherapy (ET + CT). Treatment with ET alone was found to be non-inferior to ET + CT across patients of all ages. An exploratory analysis showed that the sub-group of patients ≤50 years of age may experience a benefit in adding chemotherapy to hormonal therapy beginning at a Recurrence Score result of 16, and the benefit increases as the Recurrence Score result increases.

See the TAILORx results→

Details regarding the data used to report distant recurrence risk and absolute chemotherapy benefit, including clinical trial characteristics, sample sizes, and confidence intervals.

Now includes the patient’s menopausal status

Recurrence Score Result

The Recurrence Score result is based on the quantitative analysis of the expression of 21 genes within the patient’s tumour sample.

Prognosis

Patient’s individualised risk of distant recurrence or individualised risk of recurrence or mortality when treated with endocrine therapy alone.*

*Based on the RxPONDER trial or the SWOG-8814 study.

Prediction

The Group Average Absolute Chemotherapy Benefit is the potential reduction in distant recurrence risk across all ages within this range of Recurrence Score^® results when chemotherapy is added.^*

*Based on the RxPONDER clinical trial populations.

Confidence Interval Range

The 95% confidence intervals provide the likely range of values for these measures.

Single-Gene Scores

Quantitative ER, PR, and HER2 scores by RT-PCR, specific to your patient.

Study Details

Contains relevant study details from either the RxPONDER trial or SWOG-8814.

Additional Study Information

Displays the patient’s individualized Recurrence Score^® result in the context of the relevant study data from either RxPONDER trial or the SWOG-8814. This example shows the difference in the 5-year risk of distant recurrence when a patient with a Recurrence Score result of 12 is treated with chemotherapy and endocrine therapy vs endocrine therapy alone.